Lung cancer : (Record no. 91314)

MARC details
000 -LEADER
fixed length control field 07292cam a2200553 i 4500
001 - CONTROL NUMBER
control field ocn853707465
003 - CONTROL NUMBER IDENTIFIER
control field OCoLC
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20221128212333.0
006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS--GENERAL INFORMATION
fixed length control field m d
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr |||||||||||
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 130312s2013 nyu ob 001 0 eng
010 ## - LIBRARY OF CONGRESS CONTROL NUMBER
LC control number 2020687659
040 ## - CATALOGING SOURCE
Original cataloging agency DLC
016 7# - NATIONAL BIBLIOGRAPHIC AGENCY CONTROL NUMBER
Record control number 016416409
Source Uk
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
ISBN 9781626184503
Qualifying information ebook
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
ISBN 162618450X
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
Cancelled/invalid ISBN 162618447X
Qualifying information hbk.
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
Cancelled/invalid ISBN 9781626184473
Qualifying information hbk.
035 ## - SYSTEM CONTROL NUMBER
System control number 607834
-- (N$T)
035 ## - SYSTEM CONTROL NUMBER
System control number (OCoLC)853707465
042 ## - AUTHENTICATION CODE
Authentication code pcc
060 14 - NATIONAL LIBRARY OF MEDICINE CALL NUMBER
Classification number WF 658
Item number L963 2013
072 #7 - SUBJECT CATEGORY CODE
Subject category code HEA
Subject category code subdivision 039030
Source bisacsh
072 #7 - SUBJECT CATEGORY CODE
Subject category code MED
Subject category code subdivision 062000
Source bisacsh
049 ## - LOCAL HOLDINGS (OCLC)
Holding library MAIN
245 00 - TITLE STATEMENT
Title Lung cancer :
Subtitle a comprehensive overview
Statement of responsibility, etc
Medium [E-Book]
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Place of production, publication, distribution, manufacture New York :
Name of producer, publisher, distributor, manufacturer Nova Biomedical,
Date of production, publication, distribution, manufacture, or copyright notice [2013]
300 ## - PHYSICAL DESCRIPTION
Physical description 1 online resource
336 ## - CONTENT TYPE
Content type term text
Content type code txt
Source rdacontent
337 ## - MEDIA TYPE
Media type term computer
Media type code c
Source rdamedia
338 ## - CARRIER TYPE
Carrier type term online resource
Carrier type code cr
Source rdacarrier
490 1# - SERIES TITLE
Series statement Cancer etiology, diagnosis and treatments
504 ## - BIBLIOGRAPHY, ETC. NOTE
Bibliography, etc Includes bibliographical references and index.
505 0# - CONTENTS
Contents Intro -- LUNG CANCER: A COMPREHENSIVE OVERVIEW -- Library of Congress Cataloging-in-Publication Data -- Contents -- Preface -- Chapter I: The Pathology of Lung Cancer -- Abstract -- Introduction -- Common Lung Cancers -- Adenocarcinoma -- Squamous Cell Carcinoma -- Distinction of Adenocarcinoma from Squamous Cell Carcinoma on Biopsy Specimens -- Small Cell Carcinoma -- Large Cell Carcinoma -- Neuroendocrine Tumours -- Metastases -- Other Tumours -- Staging -- Molecular Analysis -- Conclusion -- References -- Chapter II: Introduction to Lung Cancer, its Epidemiology and Diagnosis -- Abstract -- Introduction -- International Variation in Lung Cancer Prevalence -- Age and Lung Cancer -- Host Factors and Lung Cancer Risk from Smoking -- Gender Differences in Lung Cancer Incidence -- Race -- Second-Hand Tobacco Smoke -- Non-Smoking Related Exposures for Lung Cancer -- Radon -- Occupational Exposures -- Air Pollutants -- Body Mass Index as a Risk Factor for Lung Cancer -- Non-Cancer Lung Disease -- Genetic Factors in Lung Cancer Risk -- Diagnosis of Lung Cancer -- Symptomatic Lung Cancer Detection -- Asymptomatic Disease: Incidental and Screening Detection -- Diagnosis of Suspected Lung Cancer -- Diagnosis Based on Imaging Characteristics -- Diagnostic Strategies -- Conclusion -- References -- Chapter III: The Effect of Smoking Habit Intensity, Occupation and Diet on Lung Cancer Risk in Males -- Abstract -- Introduction -- Risk Factors -- Tobacco Smoking -- Occupational Exposure -- Diet -- Case Report -- Methods -- Results -- Conclusion -- References -- Chapter IV: Lung Cancer: Treatment in Early Stage -- Abstract -- Introduction -- Adjuvant and Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer -- Evidence for Adjuvant CT -- Preoperative CT for Early-Stage NSCLC -- The Role of Adjuvant RT.
505 8# - CONTENTS
Contents Future Directions: Targeted Therapies and Genetic Predictive and Prognostic Biomarkers -- Conclusion -- References -- Chapter V: Lung Cancer: Treatment in Advanced Stages -- Abstract -- Introduction -- Treatment of Stage III Non-Small Cell Lung Cancer (NSCLC) -- Treatment of Metastatic Non-Small Cell Lung Cancer -- Initial Systemic Therapy for Advanced NSCLC without an EGFR Mutation or the ALK Fusion Oncogene -- Initial Treatment with Targeted Agents -- Second Line Therapy -- Conclusion -- References -- Chapter VI: Management of Stage III N2 NSCLC -- Abstract -- Introduction -- Staging -- Proving N2 Disease -- Treatment -- Goals of Neoadjuvant Therapy -- Current Controversies -- Conclusion -- References -- Chapter VII: Targeted Therapies in Non-Small Cell Lung Cancer -- Abstract -- Introduction -- Targeted Therapy in Lung Cancer -- EGFR -- Targeting EGFR -- VEGF and VEGFR -- Targeting VEGFR with Bevacizumab -- Targeting VEGFR with TKIs -- EML4-ALK -- Targeting EML4-ALK -- KRAS -- Targeting KRAS -- HER2 -- Targeting HER2 -- B-RAF -- Targeting B-RAF -- C-Met -- Targeting C-Met -- PI3K -- Targeting PI3K -- MEK -- Targeting MEK -- PI3K and MEK Co-Targeted Inhibition -- IGF1R -- Targeting IGF1R -- The Future of Targeted Therapy -- Conclusion -- References -- Chapter VIII: Molecular Mechanisms of Cisplatin Resistance in Lung Cancer -- Abstract -- Introduction -- Resistance Mechanisms -- Epigenetic Regulation and Cisplatin Resistance -- Novel Strategies for Overcoming Cisplatin Resistance -- Conclusion -- References -- Chapter IX: Inflammation in Lung Carcinogenesis -- Abstract -- Introduction -- Cancer Related Inflammation -- Lung Cancer and Inflammation -- Inflammatory Mediators In Lung Cancer -- Targeting Inflammation as a Therapeutic Option -- Conclusion -- References.
505 8# - CONTENTS
Contents Chapter X: The Link between Chronic Obstructive Pulmonary Disease and Lung Cancer: Novel Molecular Insights -- Abstract -- Introduction -- Hazardous Effects of Cigarette Smoking -- Carcinogenic Compounds in the Side-Stream Smoke -- Chronic Inflammation in COPD and Lung Cancer -- Genetics of COPD and Lung Cancer -- Epigenetic Phenomena and Cigarette Smoke -- Conclusion -- References -- Chapter XI: Diagnosis, Treatment and Follow-Up of Neoplastic Pericardial Disease in Lung Cancer -- Abstract -- Introduction -- Diagnosis -- Treatment -- Conclusion -- References -- Chapter XII: The Role of Claudin Proteins in Lung Tumorigenesis -- Abstract -- Introduction -- Claudin Family Proteins -- Post-Translational Modifications of Tight Junction Proteins -- Tight Junction Proteins and Lung Cancer -- Crosstalk of Claudins and Occludin with Other Signaling Pathways in Lung Cancer -- Claudins as Therapeutic Targets -- Conclusion -- Acknowledgments -- References -- Chapter XIII: The Role of the Arachidonic Acid Pathway in NSCLC Development and Progression: Novel Approaches for Therapeutic Intervention -- Abstract -- Introduction -- 1. Arachidonic Acid Metabolism: Generation and Classification of Eicosanoids -- 2. Altered Expression of Arachidonic Acid Signalling in NSCLC -- 3. Effect of the Arachidonic Acid Pathway on Tumour Cell Signalling and Proliferation -- 4. Arachidonic Acid Mediated Regulation of Tumour Cell Death -- 5. The Role of Arachidonic Acid Signalling in NSCLC Tumour Angiogenesis -- 6. Regulation of Adhesion, Migration and Invasion of NSCLC by Arachidonic Acid Pathways -- 7. Modulation of the Immune System in NSCLC by Arachidonic Acid -- 8. Targeting Arachidonic Acid Pathways Using Pharmacological and Natural Agents -- Conclusion -- References -- Index.
590 ## - LOCAL NOTE (RLIN)
Local note Master record variable field(s) change: 050
650 #0 - SUBJECT HEADINGS
Subject term Lungs
General subdivision Cancer.
650 12 - SUBJECT HEADINGS
Subject term Lung Neoplasms.
700 1# - ADDED PERSONAL NAME
Added personal author Gately, Kathy,
Relator term editor.
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE
Uniform title Cancer etiology, diagnosis, and treatments.
856 40 - ONLINE RESOURCE
Uniform Resource Identifier <a href="https://search.ebscohost.com/login.aspx?custid=ns123844&authtype=ip,shib&direct=true&scope=site&db=nlebk&db=nlabk&AN=607834">https://search.ebscohost.com/login.aspx?custid=ns123844&authtype=ip,shib&direct=true&scope=site&db=nlebk&db=nlabk&AN=607834</a>
Link text Kingston Hospital NHS Foundation Trust OpenAthens account holders click here for access
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Suppress in OPAC Do not Suppress in OPAC
588 ## - SOURCE OF DESCRIPTION NOTE
Source of description note Description based on print version record.
938 ## -
-- YBP Library Services
-- YANK
-- 10861096
938 ## -
-- EBSCOhost
-- EBSC
-- 607834
938 ## -
-- ProQuest Ebook Central
-- EBLB
-- EBL3022723
994 ## -
-- 92
-- N$T
Holdings
Withdrawn status Lost status Damaged status Not for loan Home library Current library Shelving location Date acquired Source of acquisition Total Checkouts Date last seen Uniform Resource Identifier Price effective from Koha item type
        Stenhouse Library Stenhouse Library   28/11/2022 eBook EBSCO clinical collection   28/11/2022 https://search.ebscohost.com/login.aspx?custid=ns123844&authtype=ip,shib&direct=true&scope=site&db=nlebk&db=nlabk&AN=607834 28/11/2022 Electronic book
London Health Libraries Koha Consortium privacy notice